Quince Therapeutics, Inc. Asset Resilience Ratio
Quince Therapeutics, Inc. asset resilience ratio. Quince Therapeutics, Inc. (QNCX) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Quince Therapeutics, Inc. (QNCX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Quince Therapeutics, Inc. (2018–2025)
Asset resilience ratio of Quince Therapeutics, Inc. from 2018 to 2025. This chart shows how Quince Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read Quince Therapeutics, Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Quince Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Quince Therapeutics, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Quince Therapeutics, Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Quince Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Quince Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Quince Therapeutics, Inc. Asset Resilience Ratio by Year (2018–2025)
Quince Therapeutics, Inc. asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Quince Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.77% | $11.94 Million | $93.52 Million | -17.43pp |
| 2024-12-31 | 30.20% | $34.57 Million | $114.48 Million | +0.06pp |
| 2023-12-31 | 30.14% | $54.31 Million | $180.20 Million | -13.75pp |
| 2022-12-31 | 43.89% | $45.60 Million | $103.91 Million | +16.06pp |
| 2021-12-31 | 27.83% | $37.08 Million | $133.23 Million | -7.52pp |
| 2020-12-31 | 35.35% | $66.98 Million | $189.47 Million | -3.77pp |
| 2019-12-31 | 39.12% | $48.65 Million | $124.37 Million | -25.16pp |
| 2018-12-31 | 64.28% | $46.84 Million | $72.88 Million | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more